Alder BioPharmaceuticals (ALDR) Rating Increased to Sell at BidaskClub

BidaskClub upgraded shares of Alder BioPharmaceuticals (NASDAQ:ALDR) from a strong sell rating to a sell rating in a research note issued to investors on Friday, December 29th.

ALDR has been the topic of several other reports. Mizuho reissued a buy rating and set a $32.00 price objective on shares of Alder BioPharmaceuticals in a research note on Friday, September 15th. ValuEngine upgraded Alder BioPharmaceuticals from a strong sell rating to a sell rating in a research report on Saturday, September 30th. Cowen assumed coverage on Alder BioPharmaceuticals in a report on Tuesday, September 26th. They issued an outperform rating and a $20.00 price target for the company. Canaccord Genuity assumed coverage on Alder BioPharmaceuticals in a report on Thursday, October 26th. They issued a buy rating and a $20.00 price target for the company. Finally, Royal Bank of Canada started coverage on Alder BioPharmaceuticals in a report on Thursday, September 14th. They issued an outperform rating and a $17.00 price target for the company. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $27.93.

Alder BioPharmaceuticals (NASDAQ:ALDR) opened at $17.85 on Friday. Alder BioPharmaceuticals has a 52-week low of $8.60 and a 52-week high of $25.45. The company has a market capitalization of $1,210.00, a PE ratio of -3.32 and a beta of 2.48.

Alder BioPharmaceuticals (NASDAQ:ALDR) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.21) by $0.29. During the same period in the prior year, the firm earned ($0.70) earnings per share. analysts forecast that Alder BioPharmaceuticals will post -5.14 EPS for the current fiscal year.

In other Alder BioPharmaceuticals news, insider Mark James Litton sold 16,519 shares of the stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $10.80, for a total transaction of $178,405.20. Following the sale, the insider now directly owns 116,451 shares of the company’s stock, valued at approximately $1,257,670.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 10.60% of the stock is currently owned by company insiders.

Several hedge funds have recently bought and sold shares of ALDR. Dimensional Fund Advisors LP purchased a new stake in shares of Alder BioPharmaceuticals during the 1st quarter worth about $564,000. Russell Investments Group Ltd. lifted its stake in Alder BioPharmaceuticals by 7.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 42,416 shares of the biopharmaceutical company’s stock valued at $486,000 after buying an additional 2,837 shares in the last quarter. TD Asset Management Inc. lifted its stake in Alder BioPharmaceuticals by 149.7% in the 2nd quarter. TD Asset Management Inc. now owns 42,700 shares of the biopharmaceutical company’s stock valued at $489,000 after buying an additional 25,600 shares in the last quarter. Rhumbline Advisers lifted its stake in Alder BioPharmaceuticals by 8.5% in the 2nd quarter. Rhumbline Advisers now owns 61,416 shares of the biopharmaceutical company’s stock valued at $703,000 after buying an additional 4,825 shares in the last quarter. Finally, State of Wisconsin Investment Board purchased a new position in Alder BioPharmaceuticals in the 2nd quarter valued at about $401,000. 96.80% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Alder BioPharmaceuticals (ALDR) Rating Increased to Sell at BidaskClub” was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://ledgergazette.com/2018/01/13/alder-biopharmaceuticals-aldr-upgraded-to-sell-at-bidaskclub.html.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Analyst Recommendations for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply